CLOs on the Move


 
Caring physicians, caring for people. cCARE, Californias largest private practice oncology group, focuses on compassion, prevention, research and wellness.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ccare.com
  • 1791, East Fir Avenue
    Fresno, CA USA 93720
  • Phone: 800.456.5860

Executives

Name Title Contact Details

Similar Companies

Allergy Associates Medical Group

Allergy Associates Medical Group is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ASP Events

Advanced Sterilization Products (ASP) your leaders in sterilization. To protect patients during their most critical moments | Homepage | Irvine CA United States

Astellas

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

Otonomy

Otonomy is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.